Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cibus, Inc.CBUS · Entity 6658 | Director | June 02, 2026 | June 04, 2026 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | May 26, 2021 | May 28, 2021 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | February 20, 2024 | February 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cibus, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2036-06-02 | Direct | 77,586 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 77,586 · Balance 77,586 F1: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders.
KYNTRA BIO, INC.
Report date May 26, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 395,750 |
Reported balance
After 2021-05-26 transaction · row 1
1 source rowRow 1 · 2021-05-26 · Grant · Acquired 4,700 · Balance 395,750 F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.86 · Expires 2031-05-25 | Direct | 7,800 |
Reported balance
After 2021-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-26 · Grant · Acquired 7,800 · Balance 7,800 F3: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 605,713 |
Reported balance
Holding disclosure · report date 2021-05-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 605,713 F2: Shares are held by New Ventures I, LLC. The reporting person is Managing Member of New Ventures I, LLC and has voting and investment control with respect to the shares held by New Ventures I, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
F2: Shares are held by New Ventures I, LLC. The reporting person is Managing Member of New Ventures I, LLC and has voting and investment control with respect to the shares held by New Ventures I, LLC.
F3: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
Royalty Pharma plc
Report date February 20, 2024 · Filed February 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 320,099 |
Reported balance
After 2024-02-20 transaction · row 1
1 source rowRow 1 · 2024-02-20 · Conversion · Acquired 300,000 · Balance 320,099 F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. |
| LP interests in RPI US Partners 2019, LPSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 270,000 |
Reported balance
After 2024-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-20 · Conversion · Disposed 30,000 · Balance 270,000 F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy New Ventures III LLC | 85,187 |
Reported balance
Holding disclosure · report date 2024-02-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 85,187 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 15,000 |
Reported balance
Holding disclosure · report date 2024-02-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 15,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.
F2: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 131,512 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2025-06-15 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.35 · Expires 2026-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.45 · Expires 2027-06-26 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.45 · Expires 2031-06-20 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.48 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-04-02 · Disposition to issuer · Disposed 16,757 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.79 · Expires 2033-06-22 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-04-02 · Disposition to issuer · Disposed 7,009 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share. F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.
F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F7: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2023 Filed Dec 14, 2023 22:10 UTC | Cibus, Inc. CBUS · Entity 6658 | PurchaseClass A Common Stock | 517,107 | $10.58 | $5,470,992.06 |
DisclosureSEC source: 0000950170-23-070459 · ownership.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,622,495 F3 · kind: On December 11, 2023, the Issuer entered into an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity LLC, as underwriters in respect of an underwritten registered direct offering (the "Underwritten Offering"). Pursuant to the Underwritten Offering, the underwriters placed (i) 517,107 shares of Class A Common Stock to Mr. Riggs at a purchase price of $10.58; (ii) 2,106,723 shares of Class A Common Stock to certain other investors at a purchase price of $9.00; and (iii) 50,000 Pre-Funded Warrants to purchase 50,000 shares of Class A Common Stock ("Pre-Funded Warrants") to Mr. Riggs at a purchase price of $10.57 per Pre-Funded Warrant. On December 14, 2023, the Issuer consummated the Underwritten Offering. F3 · balance_after: On December 11, 2023, the Issuer entered into an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity LLC, as underwriters in respect of an underwritten registered direct offering (the "Underwritten Offering"). Pursuant to the Underwritten Offering, the underwriters placed (i) 517,107 shares of Class A Common Stock to Mr. Riggs at a purchase price of $10.58; (ii) 2,106,723 shares of Class A Common Stock to certain other investors at a purchase price of $9.00; and (iii) 50,000 Pre-Funded Warrants to purchase 50,000 shares of Class A Common Stock ("Pre-Funded Warrants") to Mr. Riggs at a purchase price of $10.57 per Pre-Funded Warrant. On December 14, 2023, the Issuer consummated the Underwritten Offering. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 22:17 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 47,559 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001802768-23-000030 · wk-form4_1700000224.xml · derivative · entry 4 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Class A Ordinary Shares · 47,559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 22:17 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 475,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-23-000030 · wk-form4_1700000224.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. Read SEC document |
| September 30, 2023 Filed Oct 2, 2023 21:29 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 345 | $52.09 | $17,971.05 |
DisclosureSEC source: 0001209191-23-051140 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,984 Read SEC document |
| September 27, 2023 Filed Dec 14, 2023 22:10 UTC | Cibus, Inc. CBUS · Entity 6658 | OtherClass A Common Stock | 39,476 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-070459 · ownership.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,105,388 F1 · kind: On September 27, 2023, New Ventures Agtech Solutions, LLC effectuated a pro rata distribution to its members (the "Distribution") of all of the shares of Class A Common Stock, par value $0.0001 ("Class A Common Stock"), of Cibus, Inc. (the "Issuer") held by it, which were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures Agtech Solutions, LLC. Pursuant to the Distribution, (i) 63,626 shares of Class A Common Stock were distributed to the Reporting Person; (ii) 15,791 shares of Class A Common Stock were distributed to the Reporting Person's spouse; and (iii) 39,476 shares of Class A Common Stock were distributed to other members of New Ventures Agtech Solutions, LLC ("Third-Party Member Shares"), which Third-Party Member Shares the Reporting Person has no beneficial interest in. F1 · balance_after: On September 27, 2023, New Ventures Agtech Solutions, LLC effectuated a pro rata distribution to its members (the "Distribution") of all of the shares of Class A Common Stock, par value $0.0001 ("Class A Common Stock"), of Cibus, Inc. (the "Issuer") held by it, which were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures Agtech Solutions, LLC. Pursuant to the Distribution, (i) 63,626 shares of Class A Common Stock were distributed to the Reporting Person; (ii) 15,791 shares of Class A Common Stock were distributed to the Reporting Person's spouse; and (iii) 39,476 shares of Class A Common Stock were distributed to other members of New Ventures Agtech Solutions, LLC ("Third-Party Member Shares"), which Third-Party Member Shares the Reporting Person has no beneficial interest in. F2 · balance_after: Includes (i) 5,401 shares of Class A Common Stock held jointly with the reporting person's sibling and (ii) 79,417 shares of Class A Common Stock previously reported as indirectly attributable to the Reporting Person through New Ventures Agtech Solutions, LLC that were acquired by the Reporting Person pursuant to the Distribution, of which 63,626 shares of Class A Common Stock are held directly by the Reporting Person and 15,791 shares of Class A Common Stock are held indirectly through the Reporting Person's spouse. F1 · ownership.nature: On September 27, 2023, New Ventures Agtech Solutions, LLC effectuated a pro rata distribution to its members (the "Distribution") of all of the shares of Class A Common Stock, par value $0.0001 ("Class A Common Stock"), of Cibus, Inc. (the "Issuer") held by it, which were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures Agtech Solutions, LLC. Pursuant to the Distribution, (i) 63,626 shares of Class A Common Stock were distributed to the Reporting Person; (ii) 15,791 shares of Class A Common Stock were distributed to the Reporting Person's spouse; and (iii) 39,476 shares of Class A Common Stock were distributed to other members of New Ventures Agtech Solutions, LLC ("Third-Party Member Shares"), which Third-Party Member Shares the Reporting Person has no beneficial interest in. Read SEC document |
| August 08, 2023 Filed Aug 8, 2023 21:39 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045065 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,559 Underlying: Class A Ordinary Shares · 65,000 shares Expires not disclosed F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:30 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 279 | $63.32 | $17,666.28 |
DisclosureSEC source: 0001209191-23-041097 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,639 Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 7,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039694 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,509 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:11 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 7,009 | $0.00 Strike: $63.79 | $0.00 |
DisclosureSEC source: 0001209191-23-039928 · doc4.xml · derivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,009 Underlying: Common Stock · 7,009 shares Expires 2033-06-22 Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:11 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039928 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,567 Underlying: Common Stock · 1,567 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024). F2 · derivative.expiration_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024). Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | PurchaseClass A Common Stock | 1,000 | $31.50 | $31,500.00 |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 7 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,154,464 Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantCibus Common Units · Derivative | 1,505,967 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · derivative · entry 13 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,888,084 Underlying: Class A Common Stock · 1,505,967 shares Expires not disclosed F8 · derivative.exercise_price: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. F9 · price: Represents Cibus Common Units received as consideration in connection with the Merger Agreement. F8 · derivative.exercise_date: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. F8 · derivative.expiration_date: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. F4 · ownership.nature: Held by New Ventures Agtech Solutions, LLC, for which the reporting person has voting and investment power. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantCibus Common Units · Derivative | 20,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · derivative · entry 12 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,382,117 Underlying: Class A Common Stock · 20,891 shares Expires not disclosed F8 · derivative.exercise_price: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. F9 · price: Represents Cibus Common Units received as consideration in connection with the Merger Agreement. F8 · derivative.exercise_date: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. F8 · derivative.expiration_date: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. F3 · ownership.nature: Held by the Rory Riggs Family Trust, for which the reporting person is trustee and has sole voting and dispositive power with respect to the shares held by the trust. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantCibus Common Units · Derivative | 1,361,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · derivative · entry 11 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,361,226 Underlying: Class A Common Stock · 1,361,226 shares Expires not disclosed F8 · derivative.exercise_price: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. F9 · price: Represents Cibus Common Units received as consideration in connection with the Merger Agreement. F8 · derivative.exercise_date: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. F8 · derivative.expiration_date: The Cibus Common Units, together with the Class B Common Stock (collectively, "Up-C Units") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass B Common Stock | 1,505,967 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 10 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,888,084 F7 · price: Represents shares of Class B Common Stock received as consideration in connection with the Merger Agreement, with the number of such shares of Class B Common Stock equal to the number of newly issued membership units of Cibus ("Cibus Common Units"), received by the reporting person as consideration in connection with the closing of the transactions contemplated Merger Agreement. Shares of Class B Common Stock have full voting, but no economic rights. The Issuer is the managing member of Cibus, with the Issuer's only material asset consisting of Cibus Common Units. F4 · ownership.nature: Held by New Ventures Agtech Solutions, LLC, for which the reporting person has voting and investment power. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass B Common Stock | 20,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 9 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,382,117 F7 · price: Represents shares of Class B Common Stock received as consideration in connection with the Merger Agreement, with the number of such shares of Class B Common Stock equal to the number of newly issued membership units of Cibus ("Cibus Common Units"), received by the reporting person as consideration in connection with the closing of the transactions contemplated Merger Agreement. Shares of Class B Common Stock have full voting, but no economic rights. The Issuer is the managing member of Cibus, with the Issuer's only material asset consisting of Cibus Common Units. F3 · ownership.nature: Held by the Rory Riggs Family Trust, for which the reporting person is trustee and has sole voting and dispositive power with respect to the shares held by the trust. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass B Common Stock | 1,361,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 8 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,361,226 F7 · price: Represents shares of Class B Common Stock received as consideration in connection with the Merger Agreement, with the number of such shares of Class B Common Stock equal to the number of newly issued membership units of Cibus ("Cibus Common Units"), received by the reporting person as consideration in connection with the closing of the transactions contemplated Merger Agreement. Shares of Class B Common Stock have full voting, but no economic rights. The Issuer is the managing member of Cibus, with the Issuer's only material asset consisting of Cibus Common Units. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass A Common Stock | 167,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 6 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,153,464 F2 · price: Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed "Cibus, Inc.", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock. F6 · price: Represents substitute awards constituting restricted shares of Class A Common Stock granted and issued pursuant to the Cibus, Inc. 2017 Omnibus Incentive Plan upon the closing of the transactions contemplated by the Merger Agreement (the "Transactions"), whereby certain Cibus restricted profits interest units previously granted to employees of Cibus were automatically cancelled and converted into the right to receive a number of restricted shares of the Class A Common Stock, subject to the same vesting schedule as was applicable to such profits interests units prior to the closing of the Transactions. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass A Common Stock | 9,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 5 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 985,472 F1 · price: Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the "Merger Agreement"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the "Issuer", and prior to the closing of the transactions contemplated by the Merger Agreement, "Calyxt"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC ("Cibus") and certain blocker entities party thereto. F2 · price: Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed "Cibus, Inc.", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass A Common Stock | 5,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 4 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975,872 F1 · price: Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the "Merger Agreement"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the "Issuer", and prior to the closing of the transactions contemplated by the Merger Agreement, "Calyxt"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC ("Cibus") and certain blocker entities party thereto. F2 · price: Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed "Cibus, Inc.", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock. F5 · ownership.direct: Held jointly with the reporting person's spouse, Robin Riggs. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass A Common Stock | 118,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 3 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 970,471 F1 · price: Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the "Merger Agreement"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the "Issuer", and prior to the closing of the transactions contemplated by the Merger Agreement, "Calyxt"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC ("Cibus") and certain blocker entities party thereto. F2 · price: Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed "Cibus, Inc.", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock. F4 · ownership.nature: Held by New Ventures Agtech Solutions, LLC, for which the reporting person has voting and investment power. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass A Common Stock | 2,916 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 851,578 F1 · price: Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the "Merger Agreement"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the "Issuer", and prior to the closing of the transactions contemplated by the Merger Agreement, "Calyxt"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC ("Cibus") and certain blocker entities party thereto. F2 · price: Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed "Cibus, Inc.", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock. F3 · ownership.nature: Held by the Rory Riggs Family Trust, for which the reporting person is trustee and has sole voting and dispositive power with respect to the shares held by the trust. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 11:05 UTC | Cibus, Inc. CBUS · Entity 6658 | GrantClass A Common Stock | 848,662 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014329 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 848,662 F1 · price: Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the "Merger Agreement"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the "Issuer", and prior to the closing of the transactions contemplated by the Merger Agreement, "Calyxt"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC ("Cibus") and certain blocker entities party thereto. F2 · price: Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed "Cibus, Inc.", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock. Read SEC document |
| May 22, 2023 Filed May 23, 2023 00:36 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 1,750,000 | $32.82 | $57,435,000.00 |
DisclosureSEC source: 0001209191-23-031614 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,762 Read SEC document |
| May 09, 2023 Filed May 12, 2023 22:43 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029216 · doc4.xml · derivative · entry 4 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,059 Underlying: Class A Ordinary Shares · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| May 09, 2023 Filed May 12, 2023 22:43 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029216 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,756,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:01 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 313 | $54.15 | $16,948.95 |
DisclosureSEC source: 0001209191-23-022791 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,360 Read SEC document |
| March 30, 2023 Filed Mar 30, 2023 21:53 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 130,024 | $36.26 | $4,714,345.18 |
DisclosureSEC source: 0001209191-23-021649 · doc4.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,456,762 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 21:53 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 9,926 | $36.95 | $366,765.70 |
DisclosureSEC source: 0001209191-23-021649 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,586,786 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.18 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 21:59 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 150,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010719 · doc4.xml · derivative · entry 4 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,059 Underlying: Class A Ordinary Shares · 1,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 21:59 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 1,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010719 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:18 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 321 | $52.92 | $16,987.32 |
DisclosureSEC source: 0001209191-23-000190 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,047 Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 23:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 19,990 | $42.07 | $840,939.32 |
DisclosureSEC source: 0001209191-22-061057 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,722 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 23:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 120,000 | $42.33 | $5,079,924.00 |
DisclosureSEC source: 0001209191-22-058252 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,712 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.16 to $42.53 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:11 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 365 | $46.53 | $16,983.45 |
DisclosureSEC source: 0001209191-22-052198 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,726 Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 23:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 52,025 | $42.21 | $2,195,959.64 |
DisclosureSEC source: 0001209191-22-050172 · doc4.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,712 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.08 to $42.51 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 23:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 47,975 | $42.41 | $2,034,427.85 |
DisclosureSEC source: 0001209191-22-050172 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,737 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.28 to $42.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:07 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 45,000 | $43.73 | $1,967,823.00 |
DisclosureSEC source: 0000899243-22-028395 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,712 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.66 to $43.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:06 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 289 | $57.08 | $16,496.12 |
DisclosureSEC source: 0001209191-22-040561 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,361 Read SEC document |
| June 29, 2022 Filed Jun 29, 2022 22:02 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 30,000 | $42.17 | $1,265,238.00 |
DisclosureSEC source: 0001209191-22-039839 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,712 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.05 to $42.29 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:08 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 16,757 | $0.00 Strike: $55.48 | $0.00 |
DisclosureSEC source: 0001209191-22-036383 · doc4.xml · derivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,757 Underlying: Common Stock · 16,757 shares Expires 2032-06-08 Read SEC document |
| May 20, 2022 Filed May 23, 2022 20:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 123,696 | $39.28 | $4,858,655.18 |
DisclosureSEC source: 0001209191-22-031363 · doc4.xml · nonDerivative · entry 2 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,712 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $40.04 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 26,304 | $40.09 | $1,054,650.99 |
DisclosureSEC source: 0001209191-22-031363 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,408 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.29 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:08 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantCommon Stock | 257 | $61.19 | $15,725.83 |
DisclosureSEC source: 0001209191-22-022314 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,072 Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 22:46 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 60,000 | $38.59 | $2,315,322.00 |
DisclosureSEC source: 0001209191-22-021660 · doc4.xml · nonDerivative · entry 1 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,712 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.51 to $38.74 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 21, 2022 Filed Mar 21, 2022 22:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 14,322 | $39.05 | $559,288.42 |
DisclosureSEC source: 0001209191-22-020333 · doc4.xml · nonDerivative · entry 10 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures I LLC Disclosed balance after: 0 F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.71 to $39.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 21, 2022 Filed Mar 21, 2022 22:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 25,545 | $39.05 | $997,557.80 |
DisclosureSEC source: 0001209191-22-020333 · doc4.xml · nonDerivative · entry 9 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures Select Disclosed balance after: 0 F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.71 to $39.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 18, 2022 Filed Mar 19, 2022 00:12 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 15,736 | $61.35 | $965,351.67 |
DisclosureSEC source: 0001209191-22-020160 · doc4.xml · nonDerivative · entry 7 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by New Ventures I, LLC Disclosed balance after: 0 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.13 to $61.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · ownership.nature: Mr. Riggs is Managing Member of New Ventures I, LLC and may be deemed to beneficially own the securities held by New Ventures I, LLC. Mr. Riggs disclaims beneficial ownership of the securities held by New Ventures I, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| March 18, 2022 Filed Mar 19, 2022 00:12 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 4,901 | $60.63 | $297,153.51 |
DisclosureSEC source: 0001209191-22-020160 · doc4.xml · nonDerivative · entry 6 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by New Ventures I, LLC Disclosed balance after: 15,736 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.13 to $61.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · ownership.nature: Mr. Riggs is Managing Member of New Ventures I, LLC and may be deemed to beneficially own the securities held by New Ventures I, LLC. Mr. Riggs disclaims beneficial ownership of the securities held by New Ventures I, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 22:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 56,181 | $39.77 | $2,234,093.65 |
DisclosureSEC source: 0001209191-22-020333 · doc4.xml · nonDerivative · entry 8 RIGGS RORY B · CIK 0001016835 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By New Ventures III LLC Disclosed balance after: 85,187 F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.21 to $39.71 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.